Molecular Formula | C19H32N4O11 |
Molar Mass | 492.48 |
Density | 1.390±0.06 g/cm3(Predicted) |
Boling Point | 1071.8±65.0 °C(Predicted) |
Solubility | H2O: 10 mg/mL, clear, colorless |
Appearance | buffered aqueous solution |
Merck | 13,6329 |
BRN | 4220745 |
pKa | 4.44±0.10(Predicted) |
Storage Condition | -20°C |
Physical and Chemical Properties | Bioactive Muramyl dipeptide (MDP) is a common structural unit of peptidoglycan. Muramyl dipeptide induce bone formation by inducing Runx2. |
Use | Uses Adjuvant peptides are mainly used in the fields of medicine and chemical industry. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | MA2275260 |
FLUKA BRAND F CODES | 10 |
overview
Adjuvant peptide refers to a peptide that promotes or modulates the function of an antigen by inducing, enhancing and/or promoting an immune response against the antigen as a functional component (in the composition).
Target
Target Value
Runx2
in vitro studies
Muramyl dipeptide (0.1-10 µg/mL; 24 hours) increases protein expression of Runx2 in a dose-dependent manner.
Muramyl dipeptide (0.1-10 µg/mL; 6 hours) increases mRNA levels of Runx2 in a dose-dependent manner.
Western Blot Analysis
Cell Line: MC3T3-E1 cells
Concentration: 0.1, 1, 10 µg/mL
Incubation Time: 24 hours
Result: Increased protein expression of Runx2 in a dose-dependent manner.
RT-PCR
Cell Line: MC3T3-E1 cells
Concentration: 0.1, 1, 10 µg/mL
Incubation Time: 6 hours
Result: Increases mRNA levels of Runx2 in a dose-dependent manner.
In vivo studies
Muramyl dipeptide (1.25 mg/kg; I .p.; twice) alleviates bone loss induced by osteoporosis.
Animal Model: RANKL-induced osteoporosis model (Five-week-old C57BL/6 mice)
Dosage: 1.25 mg/kg
Administration: I .p.; twice (RANKL-induced osteoporosis for 3 weeks and euthanized at 4 weeks)
Result: Significantly enhanced the trabecular bone volume (BV/ TV) and trabecular number (Tb.N).